https://news.medxy.ai/zh/metabolite-driven-cognitive-recovery/Medxy AIzh2026-09-03T07:14:17-07:00代谢物驱动的肝移植后神经认知复苏：皮层网络再激活的新见解 https://news.medxy.ai/ja/liver-transplant-cognition/Medxy AIja2026-09-03T07:13:59-07:00肝移植後にメタボライトが導く神経認知機能の回復：大脳皮質ネットワーク再活性化の新知見 https://news.medxy.ai/vi/liver-transplant-metabolites/Medxy AIvi2026-09-03T07:12:21-07:00Sau ghép gan: chất chuyển hóa giúp ‘đánh thức’ lại mạng lưới vỏ não và phục hồi nhận thức https://news.medxy.ai/zh/hpv-anal-dysplasia-transplant/Medxy AIzh2026-09-03T07:07:38-07:00实体器官移植受者的HPV相关肛门发育不良：探索移植特异性的黏膜免疫失调 https://news.medxy.ai/ja/hpv-anal-dysplasia-transplant-2/Medxy AIja2026-09-03T07:05:19-07:00固形臓器移植レシピエントにおけるHPV関連肛門異形成：移植特異的な粘膜免疫機能障害を探る https://news.medxy.ai/vi/hpv-anal-dysplasia-transplants/Medxy AIvi2026-09-03T07:03:49-07:00Loạn sản hậu môn liên quan đến HPV ở người nhận ghép tạng đặc: Làm rõ rối loạn điều hòa miễn dịch niêm mạc đặc hiệu cho ghép tạng https://news.medxy.ai/hpv-associated-anal-dysplasia-in-solid-organ-transplant-recipients-exploring-transplant-specific-mucosal-immune-dysregulation/Medxy AIen2026-09-03T07:03:21-07:00HPV-Associated Anal Dysplasia in Solid Organ Transplant Recipients: Exploring Transplant-Specific Mucosal Immune Dysregulation https://news.medxy.ai/zh/neurofibromatosis1-vascular-features/Medxy AIzh2026-09-03T07:02:33-07:00神经纤维瘤病1型中的新型血管表现：樱桃样血管瘤的流行病学与机制线索 https://news.medxy.ai/ja/cherry-angioma-neurofibromatosis-1/Medxy AIja2026-09-03T07:02:15-07:00神経線維腫症1型における新たな血管性病変としてのチェリーアンジオーマ：疫学と病態機序の新知見 https://news.medxy.ai/vi/cherry-vessels-neurofibromatosis/Medxy AIvi2026-09-03T07:01:55-07:00U mạch anh đào như một biểu hiện mạch máu mới trong Bệnh u xơ thần kinh тип 1: Dịch tễ học và cơ chế bệnh sinh https://news.medxy.ai/cherry-angiomas-as-a-novel-vascular-manifestation-in-neurofibromatosis-type-1-epidemiology-and-mechanistic-insights/Medxy AIen2026-09-03T07:01:33-07:00Cherry Angiomas as a Novel Vascular Manifestation in Neurofibromatosis Type 1: Epidemiology and Mechanistic Insights https://news.medxy.ai/zh/brepocitinib-dermatomyositis/Medxy AIzh2026-09-03T07:00:51-07:00Brepocitinib 在皮肌炎中的皮肤特异性疗效：来自 3 期随机临床试验及二次分析的证据 https://news.medxy.ai/ja/brelocitinib-dermatomyositis/Medxy AIja2026-09-03T07:00:32-07:00皮膚筋炎におけるBrepocitinibの皮膚転帰：第3相ランダム化臨床試験と二次解析からのエビデンス https://news.medxy.ai/vi/brepocitinib-skin-improvement/Medxy AIvi2026-09-03T07:00:07-07:00Brepocitinib mang lại cải thiện rõ rệt trên da ở viêm da cơ: bằng chứng từ thử nghiệm ngẫu nhiên pha 3 và phân tích thứ cấp https://news.medxy.ai/skin-specific-outcomes-of-brepocitinib-in-dermatomyositis-evidence-from-a-phase-3-randomized-clinical-trial-and-secondary-analysis/Medxy AIen2026-09-03T06:59:45-07:00Skin-Specific Outcomes of Brepocitinib in Dermatomyositis: Evidence from a Phase 3 Randomized Clinical Trial and Secondary Analysis https://news.medxy.ai/a-patient-with-child-syndrome-mimicking-hailey-hailey-disease-a-diagnostic-challenge/Medxy AIen2026-09-03T06:58:58-07:00A patient with CHILD syndrome mimicking Hailey-Hailey disease: A diagnostic challenge https://news.medxy.ai/zh/serum-amyloid-protein-a/Medxy AIzh2026-09-03T06:58:23-07:00血清淀粉样蛋白A可作为皮肌炎相关快速进展性间质性肺疾病的预后生物标志物 https://news.medxy.ai/ja/amyloid-a-biomarker/Medxy AIja2026-09-03T06:58:07-07:00皮膚筋炎関連急速進行性間質性肺疾患における予後バイオマーカーとしての血清アミロイドA https://news.medxy.ai/vi/serum-amyloid-a/Medxy AIvi2026-09-03T06:57:48-07:00Serum Amyloid A: Biomarker tiên lượng trong bệnh phổi kẽ tiến triển nhanh liên quan viêm da cơ https://news.medxy.ai/serum-amyloid-a-as-a-prognostic-biomarker-in-dermatomyositis-associated-rapidly-progressive-interstitial-lung-disease/Medxy AIen2026-09-03T06:57:30-07:00Serum Amyloid A as a Prognostic Biomarker in Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease https://news.medxy.ai/zh/silicone-implant-rupture/Medxy AIzh2026-09-03T06:56:57-07:00第四代高凝聚性硅胶乳房植入物破裂与硅胶腋窝淋巴结病：临床发现与手术相关性 https://news.medxy.ai/ja/4th-gen-cohesive-breast-implant-failure/Medxy AIja2026-09-03T06:56:42-07:00第4世代コヒーシブ型乳房インプラント破損に伴うシリコーン腋窩リンパ節症：臨床的知見と手術所見との関連 https://news.medxy.ai/vi/silicone-breast-implant-complications/Medxy AIvi2026-09-03T06:54:56-07:00Viêm hạch nách do silicone liên quan đến vỡ túi độn ngực kết dính thế hệ thứ tư: phát hiện lâm sàng và tương quan phẫu thuật https://news.medxy.ai/silicone-axillary-lymphadenopathy-linked-to-fourth-generation-cohesive-breast-implant-rupture-clinical-insights-and-surgical-correlation/Medxy AIen2026-09-03T06:53:41-07:00Silicone Axillary Lymphadenopathy Linked to Fourth-Generation Cohesive Breast Implant Rupture: Clinical Insights and Surgical Correlation https://news.medxy.ai/zh/breast-augmentation-results/Medxy AIzh2026-09-03T06:53:03-07:00保留组织的乳房下皱襞乳房增大术：三年随访显示美容效果更佳、并发症更少 https://news.medxy.ai/ja/breast-augmentation/Medxy AIja2026-09-03T06:52:45-07:00組織温存を重視した乳房下溝アプローチによる乳房増大術：3年間で示された高い審美性と低合併症 https://news.medxy.ai/vi/breast-augmentation-2/Medxy AIvi2026-09-03T06:52:21-07:00Tăng kích thước vú bảo tồn mô qua nếp lằn dưới vú: cải thiện kết quả thẩm mỹ với biến chứng tối thiểu trong 3 năm https://news.medxy.ai/tissue-preserving-inframammary-fold-breast-augmentation-enhancing-aesthetic-outcomes-with-minimal-complications-over-three-years/Medxy AIen2026-09-03T06:52:03-07:00Tissue-Preserving Inframammary Fold Breast Augmentation: Enhancing Aesthetic Outcomes with Minimal Complications Over Three Years https://news.medxy.ai/zh/epidermal-stem-cells/Medxy AIzh2026-09-03T06:51:17-07:00术中快速分离表皮干细胞可提升全层创面单阶段复合皮肤移植效果 https://news.medxy.ai/ja/epidermal-stem-cell-isolation/Medxy AIja2026-09-03T06:51:00-07:00全層創傷に対する単段階複合皮膚移植を高める、表皮幹細胞の迅速分離 https://news.medxy.ai/vi/70139-2/Medxy AIvi2026-09-03T06:49:40-07:00Việc nhanh chóng tách chiết tế bào gốc biểu bì ngay trong quá trình phẫu thuật giúp cải thiện kết quả của kỹ thuật ghép da phức hợp một thì đối với các vết thương mất da toàn bộ chiều dày https://news.medxy.ai/rapid-isolation-of-epidermal-stem-cells-enhances-single-stage-composite-skin-graft-outcomes-for-full-thickness-wounds/Medxy AIen2026-09-03T06:48:29-07:00Rapid Isolation of Epidermal Stem Cells Enhances Single-Stage Composite Skin Graft Outcomes for Full-Thickness Wounds https://news.medxy.ai/zh/maxillary-distraction-osteogenesis/Medxy AIzh2026-09-03T06:47:44-07:00上颌牵张成骨：唇腭裂管理中的革新性策略 https://news.medxy.ai/ja/jawbone-extension-options/Medxy AIja2026-09-03T06:47:24-07:00口唇口蓋裂治療における上顎骨延長術――治療戦略を変える新たな選択肢 https://news.medxy.ai/vi/maxillary-distraction-approach/Medxy AIvi2026-09-03T06:47:01-07:00Maxillary distraction osteogenesis: Hướng tiếp cận mới trong điều trị khe hở môi và vòm miệng https://news.medxy.ai/maxillary-distraction-osteogenesis-a-transformative-approach-in-cleft-lip-and-palate-management/Medxy AIen2026-09-03T06:46:38-07:00Maxillary Distraction Osteogenesis: A Transformative Approach in Cleft Lip and Palate Management https://news.medxy.ai/zh/therapeutic-hypothermia-or-normothermia/Medxy AIzh2026-09-03T06:45:55-07:0035°C治疗性低体温还是控制性正常体温？ICU热射病先导RCT带来的启示 https://news.medxy.ai/ja/icu-hypothermia/Medxy AIja2026-09-03T06:45:33-07:00ICU熱中症における35℃低体温療法は有効か：パイロットRCTが示した示唆 https://news.medxy.ai/vi/therapeutic-hypothermia/Medxy AIvi2026-09-03T06:45:13-07:00Hạ thân nhiệt điều trị 35°C so với thân nhiệt bình thường có kiểm soát trong say nắng tại ICU: những ghi nhận từ một RCT thí điểm https://news.medxy.ai/therapeutic-hypothermia-2/Medxy AIen2026-09-03T06:44:48-07:00Therapeutic Hypothermia at 35°C vs. Controlled Normothermia in ICU Heatstroke: Insights from a Pilot RCT https://news.medxy.ai/ja/geographic-access-cardiogenic-shock/Medxy AIja2026-09-03T06:44:18-07:00心原性ショックの転帰を左右する地理的アクセス差―韓国全国コホートが示した実態 https://news.medxy.ai/vi/geographic-distance-cardiac-shock/Medxy AIvi2026-09-03T06:43:59-07:00Khoảng cách địa lý ảnh hưởng thế nào đến tử vong trong sốc tim? Dữ liệu từ một đoàn hệ toàn quốc tại Hàn Quốc https://news.medxy.ai/impact-of-geographic-access-on-mortality-in-cardiogenic-shock-insights-from-a-nationwide-korean-cohort/Medxy AIen2026-09-03T06:43:41-07:00Impact of Geographic Access on Mortality in Cardiogenic Shock: Insights from a Nationwide Korean Cohort https://news.medxy.ai/ja/us-adult-substance-use-treatment/Medxy AIja2026-09-03T06:42:44-07:00米国成人のアルコール・オピオイド使用障害における薬物療法受療と医療利用：2022～2023年全国データからの示唆 https://news.medxy.ai/vi/70106-2/Medxy AIvi2026-09-03T06:42:22-07:00Điều trị bằng thuốc và việc sử dụng dịch vụ chăm sóc sức khỏe ở người trưởng thành tại Hoa Kỳ mắc chứng rối loạn sử dụng rượu và opioid: Phân tích dựa trên dữ liệu quốc gia giai đoạn 2022–2023 https://news.medxy.ai/receipt-of-pharmacotherapy-and-healthcare-utilization-among-us-adults-with-alcohol-or-opioid-use-disorder-insights-from-2022-2023-national-data/Medxy AIen2026-09-03T06:40:29-07:00Receipt of Pharmacotherapy and Healthcare Utilization Among US Adults with Alcohol or Opioid Use Disorder: Insights from 2022-2023 National Data https://news.medxy.ai/zh/ehr-analysis-efficiency/Medxy AIzh2026-09-03T06:38:31-07:00借助个体化EHR分析指导，提升住院医师效率与反馈质量 https://news.medxy.ai/ja/70098-2/Medxy AIja2026-09-03T06:37:42-07:00パーソナライズされたEHR分析とガイダンスによる、レジデントの業務効率およびフィードバックの質向上 https://news.medxy.ai/vi/resident-doctor-coaching/Medxy AIvi2026-09-03T06:37:18-07:00Nâng cao hiệu quả của bác sĩ nội trú và chất lượng phản hồi nhờ coaching cá thể hóa dựa trên phân tích EHR https://news.medxy.ai/enhancing-resident-efficiency-and-feedback-through-personalized-ehr-analytics-coaching/Medxy AIen2026-09-03T06:36:59-07:00Enhancing Resident Efficiency and Feedback through Personalized EHR Analytics Coaching https://news.medxy.ai/zh/pediatric-aml-treatment/Medxy AIzh2026-09-03T06:36:25-07:00儿童复发性急性髓系白血病的治疗选择：当前趋势与比较结局 https://news.medxy.ai/ja/70089-2/Medxy AIja2026-09-03T06:36:08-07:00小児再発急性骨髄性白血病の治療選択肢：最新の動向と治療成績の比較 https://news.medxy.ai/vi/aml-relapse-treatment-children/Medxy AIvi2026-09-03T06:35:45-07:00Điều trị AML tái phát ở trẻ em: xu hướng hiện nay và kết cục so sánh https://news.medxy.ai/navigating-therapeutic-approaches-in-pediatric-relapsed-acute-myeloid-leukemia-current-trends-and-comparative-outcomes/Medxy AIen2026-09-03T06:35:26-07:00Navigating Therapeutic Approaches in Pediatric Relapsed Acute Myeloid Leukemia: Current Trends and Comparative Outcomes https://news.medxy.ai/zh/myelofibrosis-treatment-progress/Medxy AIzh2026-09-03T03:34:51-07:00骨髓纤维化治疗新进展：阿扎胞苷联合鲁可替尼II期研究最终结果积极 https://news.medxy.ai/ja/myelofibrosis-treatment-results/Medxy AIja2026-09-03T03:34:34-07:00骨髄線維症治療に新たな可能性：アザシチジン＋ルキソリチニブ第II相試験の最終結果 https://news.medxy.ai/vi/azacitidine-ruxolitinib-results/Medxy AIvi2026-09-03T03:34:16-07:00Kết quả cuối cùng pha II: Azacitidine phối hợp ruxolitinib cho thấy triển vọng trong điều trị xơ tủy xương https://news.medxy.ai/final-phase-ii-trial-results-azacitidine-plus-ruxolitinib-shows-promise-in-myelofibrosis-management/Medxy AIen2026-09-03T03:33:59-07:00Final Phase II Trial Results: Azacitidine plus Ruxolitinib Shows Promise in Myelofibrosis Management https://news.medxy.ai/zh/daratumumab-vcd-al-therapy/Medxy AIzh2026-09-03T03:33:19-07:00达雷妥尤单抗联合 VCd 显著改善新诊断 AL 淀粉样变生存结局：ANDROMEDA 试验揭示关键获益 https://news.medxy.ai/ja/d-vcd-effectiveness/Medxy AIja2026-09-03T03:33:02-07:00未治療ALアミロイドーシスの生存を有意に改善：ANDROMEDA試験が示したD-VCdの有効性 https://news.medxy.ai/vi/daratumumab-vcd-al-amyloidosis/Medxy AIvi2026-09-03T03:32:42-07:00Daratumumab phối hợp VCd giúp cải thiện sống còn rõ rệt ở AL amyloidosis mới chẩn đoán: Kết quả nổi bật từ thử nghiệm ANDROMEDA https://news.medxy.ai/daratumumab-vcd-combination-significantly-improves-survival-in-newly-diagnosed-al-amyloidosis-insights-from-the-andromeda-trial/Medxy AIen2026-09-03T03:32:23-07:00Daratumumab-VCd Combination Significantly Improves Survival in Newly Diagnosed AL Amyloidosis: Insights from the ANDROMEDA Trial https://news.medxy.ai/zh/mezigdomide-tcell-reversal/Medxy AIzh2026-09-03T03:31:42-07:00Mezigdomide通过IKZF1/IKZF3降解重塑细胞因子通路，逆转多发性骨髓瘤中的T细胞耗竭 https://news.medxy.ai/ja/mezigdomide-t-cell-activation/Medxy AIja2026-09-03T03:31:26-07:00MezigdomideがIKZF1/IKZF3分解を介してT細胞疲弊を解除し、多発性骨髄腫でサイトカイン経路を再活性化 https://news.medxy.ai/vi/mezigdomide-t-cell-exhaustion/Medxy AIvi2026-09-03T03:31:08-07:00Mezigdomide đảo ngược kiệt sức tế bào T trong đa u tủy thông qua thoái hóa IKZF1/IKZF3 và tái hoạt hóa con đường cytokine https://news.medxy.ai/mezigdomide-reverses-t-cell-exhaustion-through-ikzf1-ikzf3-degradation-and-cytokine-pathway-reinvigoration-in-multiple-myeloma/Medxy AIen2026-09-03T03:26:53-07:00Mezigdomide Reverses T-Cell Exhaustion Through IKZF1/IKZF3 Degradation and Cytokine Pathway Reinvigoration in Multiple Myeloma https://news.medxy.ai/zh/allo-hsct-septic-shock/Medxy AIzh2026-09-03T03:26:13-07:00异基因造血干细胞移植受者脓毒性休克：多中心ICU队列中的结局、预后因素及临床启示 https://news.medxy.ai/ja/septic-shock-transplant/Medxy AIja2026-09-03T03:25:48-07:00同種造血幹細胞移植レシピエントにおける敗血症性ショック：多施設ICUコホートからみた転帰・予後因子・臨床的含意 https://news.medxy.ai/vi/sepsis-after-stem-cell-transplant/Medxy AIvi2026-09-03T03:25:29-07:00Sốc nhiễm khuẩn sau ghép tế bào gốc tạo máu dị sinh: Kết cục, yếu tố tiên lượng và ý nghĩa lâm sàng từ một đoàn hệ ICU đa trung tâm https://news.medxy.ai/septic-shock-in-allogeneic-hematopoietic-stem-cell-transplant-recipients-outcomes-prognostic-factors-and-clinical-implications-from-a-multicenter-icu-cohort/Medxy AIen2026-09-03T03:25:09-07:00Septic Shock in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: Outcomes, Prognostic Factors, and Clinical Implications from a Multicenter ICU Cohort https://news.medxy.ai/zh/vexus-right-atrial-pressure/Medxy AIzh2026-09-03T03:24:31-07:00肺动脉高压中右心房压评估的VExUS验证：一项多中心研究 https://news.medxy.ai/ja/vexus-right-atrial-pressure-2/Medxy AIja2026-09-03T03:24:14-07:00肺高血圧症における右房圧評価へVExUSは有用か——多施設研究で検証 https://news.medxy.ai/vi/vexus-assessment/Medxy AIvi2026-09-03T03:23:55-07:00Thẩm định VExUS để đánh giá áp lực nhĩ phải trong tăng áp động mạch phổi: nghiên cứu đa trung tâm https://news.medxy.ai/validating-the-venous-excess-ultrasound-score-vexus-for-right-atrial-pressure-assessment-in-pulmonary-hypertension-a-multicenter-study/Medxy AIen2026-09-03T03:23:36-07:00Validating the Venous Excess Ultrasound Score (VExUS) for Right Atrial Pressure Assessment in Pulmonary Hypertension: A Multicenter Study https://news.medxy.ai/zh/head-neck-cancer-care/Medxy AIzh2026-09-03T03:22:57-07:00为头颈癌患者赋能：新型亚专科门诊姑息照护诊所的实践启示 https://news.medxy.ai/ja/head-neck-cancer-care-2/Medxy AIja2026-09-03T03:22:41-07:00頭頸部癌患者のケアを高める：新規サブスペシャルティ外来緩和医療クリニックから得られた知見 https://news.medxy.ai/enhancing-care-for-head-and-neck-cancer-patients-insights-from-a-novel-subspecialty-outpatient-palliative-medicine-clinic/Medxy AIen2026-09-03T03:22:06-07:00Enhancing Care for Head and Neck Cancer Patients: Insights from a Novel Subspecialty Outpatient Palliative Medicine Clinic https://news.medxy.ai/metabolite-mediated-neurocognitive-revival-following-liver-transplantation-insights-into-cortical-network-reactivation/Medxy AIen2026-09-03T00:08:00-07:00Metabolite-Mediated Neurocognitive Revival Following Liver Transplantation: Insights into Cortical Network Reactivation https://news.medxy.ai/zh/stylegan3-synth-video/Medxy AIzh2026-09-02T23:21:33-07:00StyleGAN3 生成的合成视频频闪镜喉部图像：真实性评估 https://news.medxy.ai/ja/stylegan3-video-realism/Medxy AIja2026-09-02T23:21:11-07:00StyleGAN3で生成した合成ビデオストロボスコピー喉頭画像のリアリズム評価 https://news.medxy.ai/vi/stylegan3-videostroboscopy/Medxy AIvi2026-09-02T23:20:52-07:00Đánh giá tính chân thực của hình ảnh thanh quản videostroboscopy tổng hợp do StyleGAN3 tạo ra https://news.medxy.ai/evaluating-realism-in-synthetic-videostroboscopic-laryngeal-images-generated-by-stylegan3/Medxy AIen2026-09-02T23:20:33-07:00Evaluating Realism in Synthetic Videostroboscopic Laryngeal Images Generated by StyleGAN3 https://news.medxy.ai/zh/redefining-disability-thresholds/Medxy AIzh2026-09-02T23:19:51-07:00重新界定功能状态量表阈值，提升儿童创伤患者残疾识别率 https://news.medxy.ai/ja/functional-status-thresholds/Medxy AIja2026-09-02T23:19:34-07:00小児外傷の障害検出を高めるためのFunctional Status Scale閾値の見直し https://news.medxy.ai/vi/adjust-fss-threshold/Medxy AIvi2026-09-02T23:19:16-07:00Điều chỉnh ngưỡng FSS để phát hiện khuyết tật tốt hơn ở trẻ em chấn thương https://news.medxy.ai/redefining-functional-status-scale-thresholds-to-improve-disability-detection-in-pediatric-trauma-patients/Medxy AIen2026-09-02T23:18:57-07:00Redefining Functional Status Scale Thresholds to Improve Disability Detection in Pediatric Trauma Patients https://news.medxy.ai/zh/11-oxoandrogens-pcos/Medxy AIzh2026-09-02T23:18:22-07:00揭示11-氧代雄激素在PCOS中的作用：表型特异性谱系与治疗反应 https://news.medxy.ai/ja/pcos-11-oxygenated-androgens/Medxy AIja2026-09-02T23:15:06-07:00PCOSにおける11-酸素化アンドロゲンの実像：表現型別プロファイルと治療反応 https://news.medxy.ai/vi/androgen-11-oxy-pcos/Medxy AIvi2026-09-02T23:13:50-07:00Androgen 11-oxy hóa trong PCOS: khác biệt theo kiểu hình và đáp ứng điều trị https://news.medxy.ai/unraveling-the-role-of-11-oxygenated-androgens-in-pcos-phenotype-specific-profiles-and-treatment-responses/Medxy AIen2026-09-02T23:13:30-07:00Unraveling the Role of 11-Oxygenated Androgens in PCOS: Phenotype-Specific Profiles and Treatment Responses https://news.medxy.ai/zh/finerenone-ckd/Medxy AIzh2026-09-02T23:12:47-07:00Finerenone在高血压性非糖尿病慢性肾脏病中的应用：FIND-CKD亚组分析新证据 https://news.medxy.ai/ja/finerenone-ckd-evidence/Medxy AIja2026-09-02T23:12:28-07:00高血圧性非糖尿病性CKDにおけるフィネレノン：FIND-CKDサブグループ解析が示すエビデンス https://news.medxy.ai/vi/finerenone-ckd-hypertension/Medxy AIvi2026-09-02T23:12:07-07:00Finerenone trong bệnh thận mạn không do đái tháo đường kèm tăng huyết áp: Bằng chứng từ phân tích dưới nhóm FIND-CKD https://news.medxy.ai/finerenone-in-hypertensive-non-diabetic-chronic-kidney-disease-evidence-from-the-find-ckd-subgroup-analysis/Medxy AIen2026-09-02T23:11:49-07:00Finerenone in Hypertensive Non-Diabetic Chronic Kidney Disease: Evidence from the FIND-CKD Subgroup Analysis https://news.medxy.ai/ja/cardiovascular-burden-cancer-diagnosis/Medxy AIja2026-09-02T23:10:53-07:00がん診断時に増える心血管疾患負担：イングランド全国コホートが示す実態と将来予測 https://news.medxy.ai/vi/cardiovascular-burden-cancer/Medxy AIvi2026-09-02T23:10:34-07:00Gánh nặng bệnh tim mạch tại thời điểm chẩn đoán ung thư gia tăng: Bằng chứng từ một đoàn hệ quốc gia ở Anh và dự báo tương lai https://news.medxy.ai/rising-cardiovascular-disease-burden-at-cancer-diagnosis-insights-from-a-national-english-cohort-and-future-projections/Medxy AIen2026-09-02T23:10:16-07:00Rising Cardiovascular Disease Burden at Cancer Diagnosis: Insights from a National English Cohort and Future Projections https://news.medxy.ai/zh/vutrisiran-efficacy/Medxy AIzh2026-09-02T23:09:37-07:00Vutrisiran在转甲状腺素蛋白淀粉样变性心肌病中的疗效稳定，合并治疗不影响获益 https://news.medxy.ai/ja/vitrisislan-efficacy/Medxy AIja2026-09-02T23:09:20-07:00背景治療に左右されないビトリシランの有効性：トランスサイレチン心アミロイドーシス治療の新たな示唆 https://news.medxy.ai/vi/vutrisiran-effectiveness/Medxy AIvi2026-09-02T23:09:03-07:00Vutrisiran duy trì hiệu quả nhất quán trong bệnh cơ tim amyloid transthyretin dù dùng kèm các liệu pháp điều trị khác https://news.medxy.ai/consistent-efficacy-of-vutrisiran-in-transthyretin-cardiac-amyloidosis-amidst-concomitant-disease-modifying-therapies/Medxy AIen2026-09-02T23:08:46-07:00Consistent Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis Amidst Concomitant Disease-Modifying Therapies https://news.medxy.ai/zh/tavr-paradox/Medxy AIzh2026-09-02T23:08:05-07:00矛盾性低流量、低梯度主动脉瓣狭窄中的经导管主动脉瓣置换术：REBOOT-PARADOX试验的新启示 https://news.medxy.ai/ja/paradoxical-asortic-stenosis/Medxy AIja2026-09-02T23:07:47-07:00逆説的低流量・低圧較差大動脈弁狭窄症に対する経カテーテル大動脈弁置換術――REBOOT-PARADOX試験から見えた臨床的示唆 https://news.medxy.ai/vi/aortic-valve-catheterization/Medxy AIvi2026-09-02T23:07:26-07:00Thay van động mạch chủ qua ống thông ở hẹp van động mạch chủ dòng chảy thấp, chênh áp thấp nghịch lý: Các phát hiện từ thử nghiệm REBOOT-PARADOX https://news.medxy.ai/transcatheter-aortic-valve-replacement-in-paradoxical-low-flow-low-gradient-aortic-stenosis-insights-from-the-reboot-paradox-trial/Medxy AIen2026-09-02T23:07:06-07:00Transcatheter Aortic Valve Replacement in Paradoxical Low-Flow, Low-Gradient Aortic Stenosis: Insights from the REBOOT-PARADOX Trial https://news.medxy.ai/zh/aficamten-hcm/Medxy AIzh2026-09-02T23:06:24-07:00Aficamten改善有症状非梗阻性肥厚型心肌病的心脏功能与结构：来自ACACIA-HCM试验的启示 https://news.medxy.ai/ja/aficamten-hcm-effects/Medxy AIja2026-09-02T23:06:06-07:00症候性非閉塞性肥大型心筋症におけるAficamtenの心機能・心構造への影響：ACACIA-HCM試験からの知見 https://news.medxy.ai/aficamtens-impact-on-cardiac-function-and-structure-in-symptomatic-nonobstructive-hypertrophic-cardiomyopathy-insights-from-acacia-hcm-trial/Medxy AIen2026-09-02T23:05:28-07:00Aficamten’s Impact on Cardiac Function and Structure in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Insights from ACACIA-HCM Trial https://news.medxy.ai/zh/azd5462-heart-failure/Medxy AIzh2026-09-02T23:04:44-07:00口服 relaxin 受体激动剂 AZD5462 在慢性心力衰竭中展现潜力：LUMINARA 试验解读 https://news.medxy.ai/ja/69955-2/Medxy AIja2026-09-02T23:04:28-07:00経口リラキシン受容体作動薬AZD5462が慢性心不全において可能性を示す：LUMINARA試験からの知見 https://news.medxy.ai/vi/69954-2/Medxy AIvi2026-09-02T23:04:08-07:00Thuốc chủ vận thụ thể relaxin dùng đường uống AZD5462 cho thấy tiềm năng trong điều trị suy tim mạn tính: Những thông tin từ thử nghiệm LUMINARA https://news.medxy.ai/oral-relaxin-receptor-agonist-azd5462-shows-promise-in-chronic-heart-failure-insights-from-the-luminara-trial/Medxy AIen2026-09-02T23:03:48-07:00Oral Relaxin Receptor Agonist AZD5462 Shows Promise in Chronic Heart Failure: Insights from the LUMINARA Trial https://news.medxy.ai/zh/69926-2/Medxy AIzh2026-09-02T22:42:09-07:00“开放式对话”与“常规治疗”，哪个对成年人心理健康危机更有效？ https://news.medxy.ai/zh/post-weight-loss-surgery-risks/Medxy AIzh2026-09-02T22:39:03-07:00减重后体形塑造手术并发症风险评估：手术、GLP-1药物、联合治疗与生活方式干预的比较 https://news.medxy.ai/ja/body-contouring-complications/Medxy AIja2026-09-02T22:35:00-07:00減量後ボディ・コントゥアリングの合併症率を検証：手術、GLP-1薬物療法、併用療法、生活習慣介入の比較 https://news.medxy.ai/vi/complication-rates-post-body-contouring/Medxy AIvi2026-09-02T22:33:17-07:00Đánh giá tỷ lệ biến chứng sau tạo hình đường nét cơ thể ở bệnh nhân đã giảm cân: so sánh phẫu thuật, điều trị GLP-1, phối hợp và thay đổi lối sống https://news.medxy.ai/evaluating-complication-rates-in-post-weight-loss-body-contouring-comparing-surgery-glp-1-pharmacotherapy-combination-and-lifestyle-approaches/Medxy AIen2026-09-02T22:31:49-07:00Evaluating Complication Rates in Post-Weight-Loss Body Contouring: Comparing Surgery, GLP-1 Pharmacotherapy, Combination, and Lifestyle Approaches https://news.medxy.ai/ja/body-contouring-outcomes/Medxy AIja2026-09-02T06:00:59-07:00減量法は術後成績に影響するか？肥満手術後のボディ・コントゥアリング手術転帰を比較する https://news.medxy.ai/vi/weight-loss-surgery-impact/Medxy AIvi2026-09-02T06:00:32-07:00Tác động của phương pháp giảm cân đến kết quả phẫu thuật tạo hình đường nét cơ thể sau giảm béo: phân tích so sánh https://news.medxy.ai/impact-of-weight-loss-methods-on-post-bariatric-body-contouring-surgery-outcomes-a-comparative-analysis/Medxy AIen2026-09-02T06:00:15-07:00Impact of Weight-Loss Methods on Post-Bariatric Body Contouring Surgery Outcomes: A Comparative Analysis https://news.medxy.ai/zh/facelift-age-risks-2/Medxy AIzh2026-09-02T05:59:21-07:00面部提升术的年龄相关风险如何评估：实际年龄真的是障碍吗？ https://news.medxy.ai/ja/facelift-age-risks/Medxy AIja2026-09-02T05:59:02-07:00フェイスリフト手術における年齢関連リスクを検証：暦年齢は障壁となるのか https://news.medxy.ai/vi/age-risk-facelift/Medxy AIvi2026-09-02T05:58:40-07:00Đánh giá nguy cơ theo tuổi trong phẫu thuật căng da mặt: Liệu tuổi theo niên lịch có phải là rào cản? https://news.medxy.ai/assessing-age-related-risks-in-facelift-surgery-is-chronological-age-a-barrier/Medxy AIen2026-09-02T05:57:58-07:00Assessing Age-Related Risks in Facelift Surgery: Is Chronological Age a Barrier? https://news.medxy.ai/zh/hidden-costs-nerves/Medxy AIzh2026-09-02T05:57:15-07:00治愈背后的隐性成本：远端上肢神经损伤后的经济负担 https://news.medxy.ai/ja/hidden-burdens/Medxy AIja2026-09-02T05:56:57-07:00治癒の裏にある見えない負担：遠位上肢神経損傷後の経済的苦難 https://news.medxy.ai/vi/silent-financial-burden/Medxy AIvi2026-09-02T05:56:31-07:00Gánh nặng tài chính âm thầm sau tổn thương thần kinh chi trên đoạn xa https://news.medxy.ai/hidden-costs-of-healing-financial-burdens-after-distal-upper-extremity-nerve-injuries/Medxy AIen2026-09-02T05:56:02-07:00Hidden Costs of Healing: Financial Burdens After Distal Upper Extremity Nerve Injuries https://news.medxy.ai/a-split-muscle-support-technique-for-direct-to-implant-breast-reconstruction-a-case-series/Medxy AIen2026-09-02T05:55:19-07:00A Split-Muscle Support Technique for Direct-To-Implant Breast Reconstruction: A Case Series https://news.medxy.ai/ja/69683-2/Medxy AIja2026-09-02T05:18:43-07:00イングランドにおける成人向けメンタルヘルス・クライシス・ケア：オープン・ダイアローグ対通常の治療――ODDESSI多施設共同クラスター無作為化試験の分析 https://news.medxy.ai/vi/open-dialogue-treatment/Medxy AIvi2026-09-02T05:17:58-07:00Open Dialogue hay điều trị thường quy: Góc nhìn từ thử nghiệm ngẫu nhiên theo cụm đa trung tâm ODDESSI ở Anh https://news.medxy.ai/open-dialogue-versus-treatment-as-usual-for-adults-in-mental-health-crisis-insights-from-the-oddessi-multisite-cluster-randomised-trial-in-england/Medxy AIen2026-09-02T05:17:39-07:00Open Dialogue versus Treatment as Usual for Adults in Mental Health Crisis: Insights from the ODDESSI Multisite Cluster-Randomised Trial in England https://news.medxy.ai/zh/genomics-psychiatry-prevention/Medxy AIzh2026-09-02T05:16:51-07:00基因组学如何助力精神病学精准预防：机遇与挑战 https://news.medxy.ai/ja/69678-2/Medxy AIja2026-09-02T05:16:33-07:00精神医学におけるゲノミクスと精密予防の推進：機会と課題 https://news.medxy.ai/vi/genomics-precision-psychiatry/Medxy AIvi2026-09-02T05:16:12-07:00Khai thác genomics để phòng ngừa chính xác trong tâm thần học: cơ hội và thách thức https://news.medxy.ai/harnessing-genomics-for-precision-prevention-in-psychiatry-opportunities-and-challenges/Medxy AIen2026-09-02T05:15:46-07:00Harnessing Genomics for Precision Prevention in Psychiatry: Opportunities and Challenges https://news.medxy.ai/zh/glp-1-cardiovascular-outcomes/Medxy AIzh2026-09-02T05:14:55-07:00GLP-1受体激动剂、死亡率与重性精神障碍患者的心血管结局：一项综合性综述 https://news.medxy.ai/ja/glp-1-mortality-review/Medxy AIja2026-09-02T05:14:31-07:00重篤な精神疾患におけるGLP-1受容体作動薬の死亡率と心血管転帰：包括的レビュー https://news.medxy.ai/vi/glp1-agonists-mental-illness/Medxy AIvi2026-09-02T05:14:07-07:00Thuốc chủ vận thụ thể GLP-1 trong bệnh tâm thần nặng: Tử vong và kết cục tim mạch dưới góc nhìn tổng quan toàn diện https://news.medxy.ai/glucagon-like-peptide-1-receptor-agonists-mortality-and-cardiovascular-outcomes-in-serious-mental-illness-a-comprehensive-review/Medxy AIen2026-09-02T05:13:43-07:00Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness: A Comprehensive Review